Cure My Disease

Don't miss your cure!

 Log in / Sign up

A phone call could unlock early cancer detection for High-Risk groups

NCT ID NCT07787156

Knowledge-focused Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time

Summary

This study tests a remote education program to help people at higher risk for pancreatic cancer learn about genetic testing and a blood test that screens for multiple cancers. The program targets Black, Latino/a, and Medicaid-enrolled individuals in Massachusetts who may have had less access to such services. Participants are randomly assigned to receive online materials alone or with a phone call from a trained educator. The goal is to see if this approach is practical, acceptable, and delivered as planned, and whether it encourages participants to pursue testing.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Telephone education session and online educational materials
What this could lead to
If successful, this approach could improve access to genetic testing and early cancer detection for underserved groups, potentially catching pancreatic cancer earlier.
What could go wrong
This is a small feasibility study, so results may not apply broadly. Participation is voluntary, and the education may not change decisions or outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 50 years or older OR 10 years younger than the earliest PDAC diagnosis in a family member * Current Medicaid enrollment and/or Black and/or Latino/a * Willingness to travel to Dana-Farber Cancer Institute in Boston, MA, for diagnostic testing if MCED screening test indicates possible malignancy * Living in the state of Massachusetts * No prior multi-gene panel genetic testing related to PDAC genetic risk * Internet access to complete study surveys * English speaking * Willing to complete study surveys * At least one first-degree relative with a PDAC diagnosis by participant report OR Any blood relative with a known pathogenic or likely pathogenic variant in a cancer susceptibility gene related to PDAC by participant report (e.g. ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, STK11, or TP53) Exclusion Criteria: * Less than age 50 years or age not within 10 years of the earliest PDAC diagnosis in their family * Cancer diagnosis in the last 3 years (excluding non-melanoma skin cancers) * Currently pregnant * Insurance other than Medicaid or race/ethnicity other than Black or Latino/a * Prior genetic testing related to PDAC genetic risk * Genetic counseling in the last 3 years * Living in a state other than Massachusetts * Language other than English * Three members of the same family already enrolled in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Family history of pancreas cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Family history of pancreas cancer Genetic testing Multi-cancer early detection Pancreatic ductal adenocarcinoma (PDAC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.